Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Blau Farmaceutica's Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was R$378 Mil. Therefore, Blau Farmaceutica's EV-to-EBIT ratio for today is 5.61.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Blau Farmaceutica's Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was R$416 Mil. Therefore, Blau Farmaceutica's EV-to-EBITDA ratio for today is 5.09.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Blau Farmaceutica's Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was R$1,373 Mil. Therefore, Blau Farmaceutica's EV-to-Revenue ratio for today is 1.54.
Blau Farmaceutica Enterprise Value Historical Data
The historical data trend for Blau Farmaceutica's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Blau Farmaceutica's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Enterprise Value falls into.
Blau Farmaceutica Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Blau Farmaceutica's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Blau Farmaceutica's current Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$378 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Blau Farmaceutica's current Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$416 Mil.
Blau Farmaceutica's current Enterprise Value is R$2,118 Mil.
Blau Farmaceutica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,373 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica Enterprise Value Related Terms
Thank you for viewing the detailed overview of Blau Farmaceutica's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Blau Farmaceutica (BSP:BLAU3) Business Description
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:BLAU3 has been successfully added to your 